Nanobiotix (NBTX) - Total Assets
Based on the latest financial reports, Nanobiotix (NBTX) holds total assets worth $67.76 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Nanobiotix (NBTX) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Nanobiotix - Total Assets Trend (2011–2025)
This chart illustrates how Nanobiotix's total assets have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Nanobiotix to see how much of total assets are deployed in long-term investments.
Nanobiotix - Asset Composition Analysis
Current Asset Composition (December 2025)
Nanobiotix's total assets of $67.76 Million consist of 92.6% current assets and 7.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 77.9% |
| Accounts Receivable | $7.68 Million | 11.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $10.00K | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Nanobiotix's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Nanobiotix stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nanobiotix's current assets represent 92.6% of total assets in 2025, an increase from 80.1% in 2011.
- Cash Position: Cash and equivalents constituted 77.9% of total assets in 2025, up from 30.8% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 11.3% of total assets.
Nanobiotix Competitors by Total Assets
Key competitors of Nanobiotix based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Nanobiotix - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.09 | 1.04 | 6.58 |
| Quick Ratio | 1.09 | 1.04 | 6.58 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $5.24 Million | $2.53 Million | $106.21 Million |
Nanobiotix - Advanced Valuation Insights
This section examines the relationship between Nanobiotix's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 65.02 |
| Latest Market Cap to Assets Ratio | 25.82 |
| Asset Growth Rate (YoY) | 0.5% |
| Total Assets | $67.76 Million |
| Market Capitalization | $1.75 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Nanobiotix's assets at a significant premium (25.82x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Nanobiotix's assets grew by 0.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Nanobiotix (2011–2025)
The table below shows the annual total assets of Nanobiotix from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $67.76 Million | +0.51% |
| 2024-12-31 | $67.42 Million | -28.20% |
| 2023-12-31 | $93.90 Million | +57.10% |
| 2022-12-31 | $59.77 Million | -41.27% |
| 2021-12-31 | $101.77 Million | -24.07% |
| 2020-12-31 | $134.03 Million | +138.47% |
| 2019-12-31 | $56.20 Million | +21.67% |
| 2018-12-31 | $46.20 Million | -19.61% |
| 2017-12-31 | $57.47 Million | +89.02% |
| 2016-12-31 | $30.40 Million | +15.08% |
| 2015-12-31 | $26.42 Million | -28.70% |
| 2014-12-31 | $37.05 Million | +398.12% |
| 2013-12-31 | $7.44 Million | -46.96% |
| 2012-12-31 | $14.02 Million | +381.38% |
| 2011-12-31 | $2.91 Million | -- |
About Nanobiotix
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small … Read more